MicroRNA 4437 (MIR4437)

MicroRNA 4437 (MIR4437) is a small, non-coding RNA molecule classified as a microRNA (miRNA). MiRNAs are typically 20–24 nucleotides in length and regulate gene expression in multicellular organisms at the post-transcriptional level, mainly by affecting mRNA stability and translation. The biogenesis of MIR4437 follows the canonical microRNA pathway: it is transcribed as a primary transcript by RNA polymerase II, processed in the nucleus by the Drosha enzyme to an ~70 nt precursor, further processed in the cytoplasm by Dicer to the mature miRNA, and subsequently loaded into the RNA-induced silencing complex (RISC). This complex recognizes target mRNAs via partial base-pairing, most commonly leading to translational inhibition or destabilization of the target mRNA[1][5]. There is currently no evidence that MIR4437 functions as a therapeutic or pharmacological target, nor are there reported drug interactions or specific mechanisms of action for therapeutics targeting MIR4437. The sequence is recognized in databases such as miRBase (hsa-mir-4437) and GeneCards (MIR4437)[1]. The gene has been associated with certain diseases via genetic correlation (e.g., arthrogryposis, distal, type 10) but its direct mechanistic or biomarker role is not established[1]. MicroRNAs in general play key roles in cellular processes including differentiation, proliferation, apoptosis, and are widely studied in the context of various diseases, especially cancer and developmental disorders[5][3][2]. However, no current literature specifically addresses detailed biological or clinical roles for MIR4437. Note: This target is correctly named, but little is functionally characterized about MIR4437 specifically. It is not considered a therapeutic target, receptor, enzyme, or transporter.

Other names

hsa-mir-4437mir-4437